Copyright (c) 2009 Yahoo! Inc. All rights reserved.http://finance.yahoo.com/q/h?s=sgmoLatest Financial News for Sangamo BioSciences, Inc.en-usWed, 9 Dec 2009 16:02:21 Etc/GMThttp://us.news2.yimg.com/us.yimg.com/p/fi/pr/40197.gifhttp://finance.yahoo.com14417http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/ap/091209/us_sangamo_biosciences_lou_gehrig_s_disease.html?.v=1Sangamo Biosciences Inc. said Wednesday that early data from a clinical trial shows its Lou Gehrig's disease drug candidate improved patients' muscle function.yahoo_finance/961377518Wed, 9 Dec 2009 16:02:21 Etc/GMThttp://us.rd.yahoo.com/finance/external/reuters/rss/SIG=118cks9u6/*http%3A//www.reuters.com/legacyArticle?duid=mtfh11720_2009-12-09_12-00-36_n08211442_newsml&rpc=44&type=marketsNewsyahoo_finance/4074262916Wed, 9 Dec 2009 12:00:36 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091209/sf23347.html?.v=1Sangamo BioSciences, Inc. announced today the presentation of preliminary data from the Phase 2 clinical trial of its ZFP Therapeutic program to develop SB-509 as a treatment for amyotrophic lateral sclerosis at a Work in Progress session at the 20th International Symposium on ALS/MND held in Berlin, Germany.yahoo_finance/2241794116Wed, 9 Dec 2009 12:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091118/sf13949.html?.v=1Sangamo BioSciences, Inc. announced today that data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease based product, SB-728-T, for HIV/AIDS were inadvertently and prematurely disclosed on the internet.yahoo_finance/1012649230Wed, 18 Nov 2009 20:30:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/091106/sgmo10-q.htmlyahoo_finance/190340838Fri, 6 Nov 2009 22:04:40 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/ap/091105/us_earns_sangamo_biosciences.html?.v=1Biotechnology company Sangamo BioSciences Inc. said late Wednesday its third-quarter loss narrowed on higher revenue from partnerships and lower research and development costs.yahoo_finance/89283046Thu, 5 Nov 2009 15:01:37 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/a/r/s/sgmo.htmlyahoo_finance/1102512724Thu, 5 Nov 2009 14:29:28 Etc/GMThttp://us.rd.yahoo.com/finance/external/trsa/rss/SIG=133ft0sve/*http%3A//seekingalpha.com/article/171339-sangamo-biosciences-inc-q3-2009-earnings-call-transcript?source=yahooyahoo_finance/2290344595Thu, 5 Nov 2009 02:10:22 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/091104/sgmo8-k.htmlyahoo_finance/293975455Wed, 4 Nov 2009 21:42:36 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091104/sf04956.html?.v=1Sangamo BioSciences, Inc. today reported third quarter 2009 financial results and accomplishments.yahoo_finance/3436680965Wed, 4 Nov 2009 21:02:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/research/earncal/20091104.html?t=sgmoyahoo_finance/1214490467Wed, 4 Nov 2009 12:07:24 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091103/sf04632.html?.v=1Sangamo BioSciences, Inc. announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 2:20 pm ET on Tuesday, November 10, 2009 at the Merriman Curhan Ford 6th Annual Investor Summit which will be held in New York City.yahoo_finance/995434267Tue, 3 Nov 2009 21:05:00 Etc/GMThttp://us.rd.yahoo.com/finance/external/mfool/rss/SIG=12me01qp7/*http%3A//www.fool.com/investing/general/2009/10/30/4-star-stocks-on-the-upswing.aspx?source=eptyholnk303100&logvisit=y&npu=yyahoo_finance/3832484961Fri, 30 Oct 2009 18:49:53 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091028/sf00995.html?.v=1Sangamo BioSciences, Inc. today announced that the company will release its third quarter 2009 financial results on Wednesday, November 4, 2009, after the market closes. The press release will be followed by a conference call at 5:00 p.m.yahoo_finance/1792646709Wed, 28 Oct 2009 20:05:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091028/sf00863.html?.v=1Sangamo BioSciences, Inc. announced today that the California Institute for Regenerative Medicine has granted a $14.5 million Disease Team Research Award to develop an AIDS-related lymphoma therapy based on the application of its zinc finger nuclease gene-editing technology in stem cells.yahoo_finance/1037205811Wed, 28 Oct 2009 20:02:00 Etc/GMThttp://us.rd.yahoo.com/finance/external/bizj/rss/SIG=12f2im6m0/*http%3A//milwaukee.bizjournals.com/milwaukee/stories/2009/10/19/daily104.html?ana=yfcpcyahoo_finance/2370207169Fri, 23 Oct 2009 17:05:22 Etc/GMThttp://us.rd.yahoo.com/finance/external/bizj/rss/SIG=12ac5lsik/*http%3A//stlouis.bizjournals.com/stlouis/stories/2009/10/19/daily37.html?ana=yfcpcyahoo_finance/3719078449Thu, 22 Oct 2009 16:05:27 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091020/sf95182.html?.v=1Sangamo BioSciences, Inc. announced today the presentation of top-line, statistically significant Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509 as a treatment for diabetic neuropathy at the Society for Neuroscience Annual Meeting held in Chicago.yahoo_finance/2552431867Tue, 20 Oct 2009 18:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/q/ud?s=SGMOyahoo_finance/199761223Mon, 19 Oct 2009 12:10:41 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/091016/175624.html?.v=1DALLAS -- StockPreacher.com announces an investment report featuring anti-cancer drug developer GenVec Inc. . The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.yahoo_finance/1653801538Fri, 16 Oct 2009 10:50:00 Etc/GMT